key: cord-0480775-3nbqbkls
authors: Kaplan, Alan D.; Greene, John D.; Liu, Vincent X.; Ray, Priyadip
title: Unsupervised Probabilistic Models for Sequential Electronic Health Records
date: 2022-04-15
journal: nan
DOI: nan
sha: 7c384550a5d5dc376b8f3554cce0c2a77696da9d
doc_id: 480775
cord_uid: 3nbqbkls

We develop an unsupervised probabilistic model for heterogeneous Electronic Health Record (EHR) data. Utilizing a mixture model formulation, our approach directly models sequences of arbitrary length, such as medications and laboratory results. This allows for subgrouping and incorporation of the dynamics underlying heterogeneous data types. The model consists of a layered set of latent variables that encode underlying structure in the data. These variables represent subject subgroups at the top layer, and unobserved states for sequences in the second layer. We train this model on episodic data from subjects receiving medical care in the Kaiser Permanente Northern California integrated healthcare delivery system. The resulting properties of the trained model generate novel insight from these complex and multifaceted data. In addition, we show how the model can be used to analyze sequences that contribute to assessment of mortality likelihood.

The use of Electronic Health Record (EHR) data collected during routine clinical care is critical to the aspirations of precision medicine [9, 15] . EHR repositories contain large amounts of wide-ranging patient and treatment information and are essential for the development of individualized treatments in the context of disease progression [14] . With the broad adoption of EHR in the US, a large variety of data types are now routinely collected over long periods of time. This has ushered in an era of research focused on the applications and development of data-analytic tools for mining historical records of medical data to drive novel insight. Broadly, the extraction of meaningful patterns through unsupervised learning [31, 23, 17, 10] and the prediction of outcomes through supervised learning [22, 43, 41, 40, 37, 16, 13, 34, 3] are two important directions.

Unsupervised methods can be applied towards many different tasks, such as prediction, imputation, and simulation; and often contain a model of the underlying structure in the data [29] . This underlying structure is not directly observed and can lead to insights that are otherwise difficult to produce, especially for large and complex data sets. Subgroup identification is one particular aspect of unsupervised learning that is of high relevance to precision medicine, since subgroups are often a driving aspect of treatment planning. In particular, probabilistic versions of unsupervised learning models are appealing because they contain a representation of the uncertainty attached to subgroup identification [8] .

However, EHR data do not readily conform to rectangular shapes required by many of these modeling approaches. Common characteristics of EHR include non-uniformly sampled and variable length sequences, known as heterogeneous data [38] . This includes, for example, collections of vital signs or laboratory results. Many existing machine learning approaches require data to be rectangular in shape, and therefore transforming the data to fit existing methods is one avenue for predictive modeling [35] . One way of accomplishing this would be to summarize sequence statistics in binned time intervals. A difficulty with this approach is selecting the width of time window and the loss of granularity within each window. In summary, information can be lost in transformation.

Mixture models are flexible and powerful latent variable formulations that provide many benefits of unsupervised learning [25] . Of clinical importance, the latent variable probabilistically associates individuals with one of several subgroups that are learned from the data. Methods based on the mixture model have been investigated in many applications using EHR data [30, 39, 4, 19, 11] . While this provides a solid foundation, it does not inherently provide a way to track changes occurring over time.

Dynamic systems models, such as the Hidden Markov Model (HMM), or predictive methods such as Recurrent Neural Networks (RNN) could address this limitation by directly incorporating temporal dynamics. HMM methods can be formulated as continuous-time models, where transition probabilities depend on inter-measurement intervals [36, 21] . Gaussian Process (GP) models capture temporal dynamics and have been developed for EHR data [7, 1, 27, 18] . RNN approaches can be used by predicting the time until an event from the current input and the time since the last input [5] . Versions of the RNNs, such as Long Short-Term Memory (LSTM) for capturing long-term dynamics have also been applied to EHR data [12] . However, these dynamic predictive approaches do not offer the ease of subgroup interpretation that the mixture model affords.

Methods that combine mixture model structures allowing for subgrouping and dynamic modeling include mixtures of HMM and mixtures of GP models [33, 26] . This includes a model for patient risk scoring [2] , clustering gene expression data [24] and COVID-19 trajectory subgrouping [6] . Several methods have been developed for application areas outside of the biomedical domain [42, 32] . Although these methods allow for subgrouping, they do not handle heterogeneous data types, including categorical items and simultaneous observations (i.e., multiple medications administered). This heterogeneous quality of EHR of data types is an important aspect that our model is designed to work with. In our approach, we develop a model that: 1) utilizes mixtures for probabilistic subgroup analysis, 2) captures temporal dynamics of data elements, and 3) conforms to the heterogeneity of data types.

Our method combines both the mixture model and temporal dynamics into one model, where entire sequences are modeled simultaneously as observations in the mixture model. This leads to each latent state representing an entire temporal trajectory. A layered set of latent variables are used that express membership across population subgroups and categorize observed data elements.

As in the mixture model approach, the top-layer latent variable is an indicator that assigns subjects to one of a set of groupings. In addition to grouping by subjects, the second layer of latent variables categorizes each data type. These latent variables are indicators for sequence categories. This results in a set of states for each data type (Medications, Laboratory Tests, etc.), each one describing probabilities for all possible sequences of the associated data type.

In this way, we decompose the dataset simultaneously across subject states and data states.

Kaiser Permanente Northern California (KPNC) is a highly integrated healthcare delivery system with 21 medical centers caring for an overall population of 4 million members. For this work, we use a dataset consisting of 244,248 inpatient hospitalization visits with a suspected or confirmed infection and sepsis diagnosis, drawn from KPNC medical centers between 2009 and 2013 [20] .

We consider time-dependent data elements that appear along a subject's timeline. Upon hospitalization (at time 0), Age, Sex, and Admission Diagnoses are collected. The Admission Diagnoses are ICD9 codes that are assigned early in the hospitalization, typically at the transition between emergency department and inpatient care. As the patient moves through the hospital, we record the sequence of Beds that they are admitted to. We capture sequences of both Laboratory Tests and Neurological Tests, in which multiple tests may occur at the same timepoint. From the Laboratory Tests, we extract the test type, but not the test result. The Neurological Tests consist of neurological evaluations and mental status nursing-based flowsheet assessments including relevant assessment (e.g., Glasgow Coma Score) and the result.

Medications are recorded throughout the episode and are categorized by therapy class (a grouping of specific medications). As in the case of Laboratory Tests and Neurological Tests, multiple instances may be given at a single timepoint. For this work, we did not extract the dosage or frequency of usage.

Notation used for these data streams associated with each episode are shown in Table 1 . Bold symbols indicate vectors of values. In cases where we refer to any of these streams, we use the symbol x. The number of values in x is |x|. Note that for Laboratory Tests, Neurological Tests, and Medications, more than one item is possible at each time point. This means that in general λ, ν, and µ contain sequences of varying length. The complete collection of data for one episode is: y = (φ a , φ s , φ d , β, α, δ, λ, ν, µ). 

In this section we describe the probabilistic model that computes the likelihood of an episode, f (y). Our model for this collection of data keeps intact its structure and does not require any reformatting or time binning. Figure 1 shows the structure of the model. Blue shapes represent latent variables and arrows indicate conditional dependencies. Each leaf in this figure is a sub-model for that specific data sequence (further illustrated in Figure 2 ).

The model consists of a top-layer latent state (Z) that links the different data elements and sequences. Under the model, the variables and sequences of an episode are conditionally independent given the latent variable, so that

Each term in this expression is a distribution with learned parameters used to model individual data streams. The distribution of the overall model is formed by summing over the latent variable, where α z ≥ 0 is a mixing coefficient such that z α z = 1. Note that since the latent variable is unknown, the components of the episode are not independent under the model. For example, the likelihood of Age given Sex under this model is f (φ a |φ s ) = z pzf (φa|Z=z)f (φs|Z=z)

On the other hand, if the model treated all components to be independent, then this would evaluate to the marginal, f (φ a ), without considering Sex.

An important aspect of the model is the use of mixture models for the constituent sub-models. This leads to a layered model structure, resulting in a mixture of mixture models. Each sub-model has mixing coefficients dependent on the top-layer component. The model can be interpreted as building up a representation of the multi-sequence data, starting with states for individual sequences at the lower layer. The top layer states captures dependencies between these lower layer states. Figure 2 shows the sub-model structures used to model the individual data sequences. The colors in this figure correspond to the colors used in Figure 1 . Each green circle represents a single data element (e.g., one laboratory result or medication). The # symbol captures the length of the sequence. See Appendices A for the generative process describing how episodes can be sampled using the model and Appendix B for a full description of its probability density function.

Admission Diagnoses contain a set of ICD9 codes given at hospital admission, and Discharge Diagnoses contain a set of ICD9 codes given at discharge. For each of these data elements there is no sequence or temporal information, as they occur simultaneously. A mixture is used to capture these sets of codes, where each state contains a probability distribution over sets of codes (see Figure 2a ). The number of items (for each state) is described by a Poisson distribution. Within each state, the likelihood of the codes themselves are given by a categorical distribution over the ICD9 codes.

The Beds, Laboratory Tests, Neurological Tests, and Medications sequences are temporal and have items occurring throughout the hospital stay. For these, we use model structures that distinguish the different collection times, rather than lumping them into one collection. Two distinctions between Beds and the other sequential streams motivate using different sequence model structures. First, only one instance of Beds can occur at a time. And secondly, there are a small number of possible Beds, whereas there are a much larger set of possible items withing the Laboratory Tests, Neurological Tests, and Medications sequences.

The model structure used to describe the Beds sequence is a mixture of Markov chains, where each state contains a Markov chain (see Figure 2b ). The length of the sequence is characterized by a Poisson distribution. The Markov chain includes an initial distribution over the set of possible values describing the first item and transition probabilities between sequential items.

For Laboratory Tests, Neurological Tests, and Medications, we use a mixture of Hidden Markov Models (HMMs) (see Figure 2c ). Similarly to the Beds model, a Poisson distribution describes the length of the sequence. Within each state of the HMM, multiple items can occur simultaneously. Therefore, each state contains its own length distribution governed by a Poisson rate, and a categorical distribution to describe the collection of items.

Parameter sharing is used to reduce complexity and improve interpretation of the trained model: parameters within the HMM states are shared across mixture states. This leads to an interpretation of a fixed vocabulary that describes each multi-item instance of Laboratory Tests, Neurological Tests, and Medications. The initial and transition probabilities are different across sub-model states to capture a range of different likely sequences.

The top-layer latent state, Z, controls the proportions of the underlying mixture models. For example, latent state Z = 4 may describe a higher likelihood for sub-model state #4 for the Laboratory Tests and sub-model state #8 for the Medications, etc. In this way, the model captures co-occurrence of the data streams. This can be used, for example, to examine which Beds are likely to occur with a specific Medications sequence.

Each of the sub-models have common parameters across the top-level components. For example, the Markov chain parameters for Beds state #2 is the same for all top-layer states. The only parameters that change in this example are the mixing coefficients for the Beds mixture. See Appendices A and B for complete details of the generative model and probability density function. Table  3 summarizes the three types of latent variables included in the model. Layer Name Notation Data Elements 1

Top-layer states z All 2

Sub-model states z β , z α , z δ , z λ , z ν , z µ All 3

HMM states s λ , s ν , s µ Laboratory Tests, Neurological Tests, Medications 

The estimation of the model parameters follows the standard Expectation Maximization (EM) procedure, see e.g. [28, 25] . Because the conditional dependence structure is a tree, message passing algorithms can be used to compute the required quantities. Given a set of episodes, y 1 , . . . , y N we seek to maximize the log-likelihood N i=1 log z p z f (y i |Z = z). The complete data consists of the episodes, y 1 , . . . , y N , the latent variables, Z, Z α , Z δ , Z β , Z λ , Z ν , Z µ , and the HMM state sequences S λ , S ν , S µ . We refer to all of the latent variables as Z. The complete data log-likelihood is, log f (y,

where the indicator I (·) equals 1 when · is true, and otherwise 0. The expected complete data log-likelihood is,

where γ i (z) = f (z|y). In turn, this likelihood can be written in terms of expected sub-model complete data log-likelihoods,

The expected complete data loglikelihoods for λ, ν, and µ are the same as for HMMs and are omitted in this description. The EM algorithms proceeds by iterating between calculating gamma and maximizing the expected complete data log-likelihood function.

In this section, we describe the approach used for model selection. The hyperparameters of the model are:

• the number of top-layer latent states: |Z|,

• the number of each sub-model latent states:

• the number of HMM states: |S λ |, |S ν |, |S µ |.

Note that the number of HMM states is the same across sub-model latent states. This leads to a total of 10 hyperparameters. Model selection is performed using the Bayesian Information Criterion (BIC) as a guide. The BIC penalizes the model fit by a function of the number of parameters:

where d is the total parameter count and N is the number of episodes. To aid in selecting hyperparameters, we first determine those relating to the lower layers, followed by the top-layer.

To determine these hyperparameters, we first perform linear searches for each sub-model individually. For the mixture of HMM sequence models (Laboratory Tests, Neurological Tests, and Medications), we employ the following strategy:

• Train a sequence of HMMs with increasing state space,

• Compute the BIC for each model, and select the number of HMM states with the lowest corresponding BIC value,

• Train a sequence of mixtures of HMMs with increasing state space using the number of HMM states determined previously,

• Compute the BIC for each model, and select the number of mixture components with the lowest corresponding BIC value.

For the Beds model we perform the following:

• Train a sequence of mixtures of Markov chains with increasing state space,

• Compute the BIC for each model, and select the number of mixture components with the lowest corresponding BIC value.

The collection models (Admission Diagnoses and Discharge Diagnoses) use a similar procedure:

• Train a sequence of collection mixtures with increasing state space,

• Compute the BIC for each model, and select the number of mixture components with the lowest corresponding BIC value.

Once these hyperparameters are determined, we can use them to train the entire model. The number of top-level states can then either be determined again using a linear search over BIC values, or assigned to a pre-selected value. When training the full model, we do not use model parameters determined previously and re-train the entire model, fixing only the hyperparameters.

We used 195,398 episodes to train the model. Following the procedure outlined in Section 4.1, we determined the number of HMM states for the Laboratory Tests, Neurological Tests, and Medications. Then, fixing those hyperparameters, we optimized for the number of mixture states for each sub-model. Both of these were done by searching over every 10 values, e.g., 10, 20, 30, etc. Table 4 shows the optimal number of states found using the model selection approach. To enable more straightforward interpretation of the model, we set the number of top-layer states to 10. We then train all parameters of the final model using these hyperparameters.

The top-layer component probabilities are shown in Figure 3a in decreasing order. This ordering of the components is preserved throughout the paper. Figure 3c shows that the probability of Death varies across components. Enrichment of mortality can be defined with respect to each top-layer component. Further, we can determine sub-model states (corresponding to e.g. Beds, Medications, etc.) that are enriched for mortality. This is done by computing

where z is the top-layer state and z x is the state for sub-model x. This is performed for each sub-model to determine which states have the greatest and least contribution to Death. Table 5 shows the probability of Death given the state for each model.

The likelihood of Beds sequences for the lowest Death risk state is shown in Figure 4a . These sequences are determined from the Markov chain for that state. Probabilities in the tree graph indicate the likelihood of Beds sequences terminating at the corresponding edge. For example, the OB → FLR sequence has a likelihood of 15%. Only sequences with likelihood of 1% or greater are shown. Figure 4b shows the sequence likelihoods for the highest risk state.

Each row in Figure 4c corresponds to a Laboratory Tests HMM state, with the three most prevalent items in the first column. Each numbered column represents the time step, and the arrows indicate the most likely sequence through the HMM states for the high and low risk Laboratory Tests states. This is computed by finding the most likely state sequence in the Laboratory Tests HMM for these two states.

For Neurological Tests, Table 4d shows the likelihood ratio between Normal and Abnormal results for each Neurological Tests test. Within each cell, the top value is the ratio for the high risk state, and the bottom value is the ratio for the low risk state. Entries with '−' indicate that the test is unlikely to be administered (probability < 1%). For example, initially (at timestep 0), Consciousness Level is 26 times as likely to be normal than abnormal for both the high and low risk groups. At timestep 1, however, abnormal results are 25 times as likely for the high risk state, while the test is unlikely to be administered for the low risk state. Figure 4e shows the most likely Medications sequences for the high and low risk states over time. Each row corresponds to an HMM state, and the first column contains the three most likely therapy classes for that HMM state. Figure 5 shows the distributions of the sub-model states for each of the top-layer components. The height of each bar is the probability α z of each component (same as Figure 5 ). Within each bar are 10 sections, each one corresponding to a sub-model state. The height of these bars are the probabilities of the sub-model state for the given top-layer state, α z f (z x |z). They are ranked and color-coded by the mortality enrichment probabilities computed in Section 5.3, from lowest risk (light red) to highest risk (dark red). Figure 6 shows the state distributions across these 10 components for Admission Diagnoses and Discharge Diagnoses.

The length parameters, which are the mean number (Poisson rate) of items in each state for Beds, Laboratory Tests, Neurological Tests, and Medications are shown in Figure 7 . The same color-coding by mortality enrichment is used in these figures as in Figures 5 and 6 .

Of the 10 states shared across Admission Diagnoses and Discharge Diagnoses, 5 were predominantly associated with Admission Diagnoses and 5 with Discharge Diagnoses. Table 6 shows the 5 most likely ICD9 diagnosis codes for each state associated with Admission Diagnoses. Each column corresponds to a state and column headings contain the prevalence of the state, z w zs . The states are sorted in ascending order according to their mortality enrichment. Similarly, Table 7 shows the 5 most likely ICD9 codes for states associated with Discharge Diagnoses.

Beds sequences for each states are shown in Figure 8 . Each subfigure is a tree which shows the likelihood of the sequence formed by tracing from the initial bed. This is computed by taking the initial state probabilities and forward simulating the Markov chain for each state. The likelihood of the sequence terminating at a node in the graph is specified in the figures. We stopped once the likelihood dropped below 1%. The states are sorted in ascending order according to their mortality enrichment.

The most likely Medications sequences for are shown in Figure 9 . Each row corresponds to an HMM state, with the three most likely therapy classes listed in the first column. Each label column corresponds to a timestep, and arrows through the HMM states over time indicate the most likely sequence for each state. These states are ordered roughly in order of their temporal appearance in these most likely sequences. Colors correspond to the ordering of mortality enrichment by state. Figure 4a shows the Beds sequences with the lowest enrichment. Figure 4b shows the sequences with the highest enrichment. Figure 4c shows the most likely sequences through HMM states for the lowest and highest enrichment. Figure 4d shows likelihood ratios for abnormal vs normal Neurological Tests results for the low risk (bottom) and high risk (top) states. Figure 4e shows the most likely Medications sequences through he HMM states for the two states. (a) S1

OR 68% (j) S10 

The model selection procedure resulted in 10 mixture states for each sequence (Table 4 ). For the Laboratory Tests, Neurological Tests, and Medications submodels, the number of HMM states was higher (90, 70, 40, respectively). In our results, we estimated models increasing the number of states by 10 each time. Further granularity would be possible, at higher computational cost. Going a layer below these top-layer results, we examine mortality enrichment by computing the likelihood of Death given a sub-model state. This results in 10 likelihoods for each sub-model ( Figure 5 . States are sorted in increasing order of Death probability. Note that the states are distinct across sub-models (state 1 is not the same state for Beds and Laboratory Tests). These distributions generally start near 0% and rise to 20% -30%. Generally there is a sharp increase in risk from state S7 to S8, although this is less apparent with Neurological Tests. Figure 4 characterizes the lowest and highest risk states for Death enrichment. For Beds, the lowest risk state is mostly related to Obstetrics ( Figure  4a ). The highest risk state (Figure 4b ) is likely to start at the emergency department (ED). The HMM sub-models (Laboratory Tests, Neurological Tests, and Medications) have an additional layer of latent states. The temporal dynamics is described by likelihoods through these HMM states. Likelihood of abnormal Neurological Tests results is generally much higher for the high mortality risk state (Figure 4d) . The low risk Medications state is most likely to proceed through two states, whereas the high risk state passes through five different states (Figure 4e ). Note that this is only the single most likely trajectory through the HMMs, and many other state sequences are also possible. Figure 5 shows how the sub-model states distribute across each top-layer component. These are ranked and color-coded by the mortality risk computed in Section 5.3. The total probability of each component is the component probability α z (same as in Figure 3a ). It can be seen that components 5 and 10 (highest Death probability) tend to have darker colored states. The same is shown in Figure 6 for Admission Diagnoses and Discharge Diagnoses. Figures 3 and 5 can be used to link sub-model states with the top layercomponents. For example, Figure 3b shows that component 8 has the highest likelihood of female Sex. Examining the Beds states that make up this component from Figure 5a , we see that this component includes the lowest mortality risk state (lightest color). Figure 8a shows that OB is a likely visit in this state.

From the mean lengths shown in Figure 7 , we can see that for Laboratory Tests and Neurological Tests there is generally an increase in the mean length as the mortality risk increases. The Medications instances are grouped by therapy classes and not individual medications, and this may be the reason why this pattern is not observed. The number of total Beds is typically much lower and this may be why the pattern is not evident for Beds. In all cases, the highest mortality risk state has the highest length parameter. Tables 6 and 7 show the most likely (top 5) ICD codes for Admission Diagnoses and Discharge Diagnoses, respectively. The Admission Diagnoses and Discharge Diagnoses sub-models share the same set of 10 diagnosis states, but only 5 distinct states for each have significant probabilities greater than 0%. These tables show only those 5 states that have significant probabilities. The 5 states in Table 7 for Discharge Diagnoses total 98.4%, so there is a small likelihood of the other states to be in the Discharge Diagnoses. These states are sorted by mortality enrichment. For example, the highest mortality risk Admission Diagnoses state contains Atrial fibrillation and Congestive heart failure in the top 5 codes. Figures 8 and 9 show the likelihood of Beds and Medications sequences across states, respectively. These are sorted and color coded by mortality risk as well. Note that the states contain probabilistic representations and the results in Figure 9 shows only the most likely trajectory through the HMM state space.

In this work we formulated a statistical model for sequences of varying length, as commonly found in EHR data. An important characteristic of the model is a layered set of latent variables. The top-layer latent variable controls dependence between the sequences, and can be interpreted as a subject subgroup indicator. Sub-model states express subgroupings in the sequence space. Having both layers of latent variables provides an intuitive way of explored the trained model, through subgroups of subjects and subgroups of likely sequences. The intersection of these subgroups can be examined to uncover phenotypes for specific conditions of interest. Sequence lengths are explicitly modeled through Poisson distributions, enabling us to distinguish sequences of varying lengths. We trained the model using EHR data and explored its internal representations through probability distributions.

In this work, we chose not to include vitals such as heart-rate and respiratoryrate. Although it is possible to include vitals as another sequence, they were left out because they are often sampled at a high rate and would require significant additional model training. In addition, it would be possible to incorporate more detailed outcome assessments as well.

An aspect of the data that is not captured by our model is the explicit time-dependence. We do incorporate sequence order for Beds and Medications sequences, but the distribution of time point is not captured. This can be accomplished in a number of different ways, ranging from modeling the average arrival times (for example, with Exponential distributions) to full time-dependent sequence models. Additional model complexity comes at the cost of requiring more data, and the choice should depend on the specific application at hand.

As the ability to integrate heterogeneous data streams is an important aspect of precision medicine, we believe that this methodology hold promise towards the development of decision support systems. Using data from Kaiser Permanente Northen California, we have shown how the models described can be used to subgroup patients and interpret these subgroups based on likely trajectories of data elements such as Laboratory Tests, Medications, and Beds. Such patterns are often difficult to uncover because they are hidden within long sequences. We showed how we can analyze sequences that contribute to the assessment of mortality risk. In future work, this inference can be expanded to other areas, such as risk of disease, or length of hospital stay. Also, since the model is a full likelihood function of the data, conditional probabilities can be computed between any subsets of the sequences to flexibly infer future sequence values.

This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344 and was supported by the LLNL LDRD Program under Project 19-ERD-009. VXL was supported in part by NIH R35GM128672.

-Draw a set of k λ,s λ Laboratory Tests for each instance by taking repeated draws of a Categorical distribution, conditioned on the state: (1 − p d,z ) φ d .

For the Beds sequence we use a mixture of Markov chains, where the length of the sequence is captured by Poisson distribution. The distribution is,

|β|! e −l β,z β p β,z β ,β1

where p β,z β ,i is the probability that the first item is i conditioned on Z β = z β , and q β,z β ,i,j is the probability of transitioning from item i to j conditioned on Zβ = z β . For Admission Diagnoses and Discharge Diagnoses we use mixtures over products of categorical distributions. The length of each of these sequences for the entire episode (|α| for Admission Diagnoses and |δ| for Discharge Diagnoses) is modeled using a Poisson distribution. For these sets we have,

where p x,zα,i is the probability of item i in sequence x for sub-model latent state z α , and p x,z δ ,i is the probability of item i in sequence x for sub-model latent state z δ The Laboratory Tests, Neurological Tests, and Medications sub-models can have multiple items at any timepoint. This is modeled using HMMs, where where the HMM transitions there a latent state sequence, S, over time. Each state can have any number of observations, drawn from a categorical distribution. The number of observations is captured with a Poisson distribution conditioned on the state. In this way we are able to model the ordered sequence and express multiple simultaneous observations. A mixture of these HMM models is used for the Laboratory Tests, Neurological Tests, and Medications observations. This distributions for these are, 

Bayesian inference of individualized treatment effects using multi-task gaussian processes

Personalized risk scoring for critical care prognosis using mixtures of gaussian processes

Predicting suicidal behavior from longitudinal electronic health records

Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records

Doctor AI: Predicting clinical events via recurrent neural networks

Hierarchical gaussian processes and mixtures of experts to model COVID-19 patient trajectories

Learning to detect sepsis with a multitask gaussian process RNN classifier

Probabilistic machine learning and artificial intelligence

Precision medicine: From science to value. Health Aff

Probabilistic modeling personalized treatment pathways using electronic health records

Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models

Predicting the risk of heart failure with EHR sequential data modeling

Learning representations for the early detection of sepsis with deep neural networks

The evolving use of electronic health records (EHR) for research

Precision medicine

Methodological variations in lagged regression for detecting physiologic drug effects in EHR data

Hierarchical bayesian nonparametric models for knowledge discovery from electronic medical records

Deep bayesian gaussian processes for uncertainty estimation in electronic health records

An infinite mixture model for coreference resolution in clinical notes

The timing of early antibiotics and hospital mortality in sepsis

Efficient learning of Continuous-Time hidden markov models for disease progression

Machine learning in infection management using routine electronic health records: tools, techniques, and reporting of future technologies

Flexible, cluster-based analysis of the electronic medical record of sepsis with composite mixture models

Clustering gene expression time series data using an infinite gaussian process mixture model

Finite Mixture Models

An alternative infinite mixture of gaussian process experts

Nonstationary multivariate gaussian processes for electronic health records

The expectation-maximization algorithm

Machine Learning: A Probabilistic Perspective

Two-Step heterogeneous finite mixture model clustering for mining healthcare databases

Learning probabilistic phenotypes from heterogeneous EHR data

Gaussian mixture based HMM for human daily activity recognition using 3D skeleton features

Infinite mixtures of gaussian process experts

A study of generalizability of recurrent neural network-based predictive models for heart failure onset risk using a large and heterogeneous EHR data set

Deep EHR: A survey of recent advances in deep learning techniques for electronic health record (EHR) analysis

Continuous time bayesian network classifiers

Machine learning for suicide risk prediction in children and adolescents with electronic health records

Heterogeneous data and big data analytics

Secure stochastic ECG signals based on gaussian mixture model for e-Healthcare systems

Prediction modeling using EHR data: challenges, strategies, and a comparison of machine learning approaches

AutoScore: A machine Learning-Based automatic clinical score generator and its application to mortality prediction using electronic health records

Mixture of HMM experts with applications to landmine detection

Defining disease phenotypes in primary care electronic health records by a machine learning approach: A case study in identifying rheumatoid arthritis

The generative picture hinges on an underlying and unobserved state z. Under the model an episode y may be sampled by performing the following:• Draw a state z from a categorical distribution: z ∼ Categorical (p)• Draw an Age using a quantized Gaussian distribution, conditioned on the top-layer state: φ a ∼ N q µ z , σ 2 z • Draw the Sex using a Bernoulli distribution conditioned on the top-layer state: φ s ∼ Bern (p s,z )• -Draw a Laboratory Tests HMM state sequence from a Markov Chain: s λ ∼ M arkovChain p λ,z λ , q λ,z λ -Draw the number of Laboratory Tests given for each instance from a Poisson distribution, conditioned on the state: k λ,s λ ∼ P oisson (l L,s λ )

For Age, we use a quantized and truncated Gaussian distribution. This conditional distribution is,where the normalizing value ensures that the distribution sums to 1, C = For Sex and Death, we we use Bernoulli distributions,where p z,z λ is the probability of sub-model state z λ given the top-layer state z, p λ,z λ ,i is the probability that state i is the initial state, q λ,z λ ,i,j is the transition probability from HMM state i to HMM state j, and p λ,z λ ,i,j is the probability of medication j conditioned on HMM state i and sub-model state z λ . And the same holds (substituting ν or µ for λ) for the Neurological Tests and Medications models.The complete set of parameters is shown in Table B .8, along with the number of parameters in each category. In this Table, |Z| is the number of top-layer latent states, |Z x | is the number of sub-model latent states for model x, C x is the number of possible items in x. The number of HMM states is C S,x for HMM model x.

Parametersl β,z β , p β,z β ,i , q β,z β ,i,j 1 + C β + C 2 β |Z β | Laboratory Tests l λ,z λ , p λ,z λ ,i , q λ,z λ ,i,j , p λ,z λ ,s,i 1 + C S,λ + C 2 S,λ + C S,λ C λ |Z λ | Neurological Tests l ν,zν , p ν,zν ,i , q ν,zν ,i,j , p ν,zν ,s,i 1 + C S,ν + C 2 S,ν + C S,ν C ν |Z ν | Medications l µ,zµ , p µ,zµ,i , q µ,zµ,i,j , p µ,zµ,s,i 1 + C S,µ + C 2 S,µ + C S,µ C µ |Z µ |